Treat postmenopausal osteoporosis before it gets worse

Osteoporosis treatments can be broadly grouped into 2 classes1

During the 5 to 6 years after menopause, there is an accelerated rate of bone resorption that exceeds bone formation2

  • Average bone loss is 10%, and some women lose up to 20%2
Overview of MOA for anabolic agents and antiresorptive agents

Discover the mechanism of action of abaloparatide

Discover the mechanism of action
of abaloparatide

References: 1. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97(2):311-325. 2. Ji M-X, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):9-13. 3. Khan A-W, Khan A. Anabolic agents: a new chapter in the management of osteoporosis. J Obstet Gynaecol Can. 2006;28(2):136-141. 4. Seeman E, Martin TJ. Co-administration of antiresorptive and anabolic agents: a missed opportunity. J Bone Miner Res. 2015;30(5):753-764.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.   All rights reserved.    05/19.   TYM-US-02572

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.
All rights reserved. 05/19.
TYM-US-02572

Back to Top